Amryt Pharma Stock Forecast, Price & News

Amryt Pharma (NASDAQ:AMYT) Frequently Asked Questions

Is Amryt Pharma a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amryt Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amryt Pharma stock.
View analyst ratings for Amryt Pharma or view top-rated stocks.

Are investors shorting Amryt Pharma?

Amryt Pharma saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 161,500 shares, a decrease of 30.2% from the October 31st total of 231,300 shares. Based on an average daily volume of 121,000 shares, the days-to-cover ratio is currently 1.3 days.
View Amryt Pharma's Short Interest.

When is Amryt Pharma's next earnings date?

Amryt Pharma is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Amryt Pharma.

How were Amryt Pharma's earnings last quarter?

Amryt Pharma plc (NASDAQ:AMYT) issued its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.14. The business earned $56.52 million during the quarter, compared to analyst estimates of $52.34 million. Amryt Pharma had a negative net margin of 41.64% and a negative trailing twelve-month return on equity of 73.58%.
View Amryt Pharma's earnings history.

What guidance has Amryt Pharma issued on next quarter's earnings?

Amryt Pharma issued an update on its FY 2021 earnings guidance on Monday, October, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $220 million-$225 million, compared to the consensus revenue estimate of $221.14 million.

What price target have analysts set for AMYT?

4 equities research analysts have issued twelve-month price targets for Amryt Pharma's stock. Their forecasts range from $19.00 to $45.00. On average, they anticipate Amryt Pharma's stock price to reach $29.50 in the next twelve months. This suggests a possible upside of 206.7% from the stock's current price.
View analysts' price targets for Amryt Pharma or view top-rated stocks among Wall Street analysts.

Who are Amryt Pharma's key executives?

Amryt Pharma's management team includes the following people:

• Dr. Joseph A. Wiley, CEO & Director (Age 50, Pay $1.72M)
• Mr. Rory P. Nealon, CFO, COO & Company Sec. (Age 53, Pay $931k)
• Ms. Elizabeth Varki Jobes J.D., Sr. VP & Global Chief Compliance Officer (Age 54)
• Mr. John McEvoy, Gen. Counsel
• Mr. Stephen Joyce, VP of Global Marketing
• Ms. Julie Eastwood, Head of HR
• Ms. Derval O'Carroll, Head of Regulatory Affairs
• Mr. Gerry Gilligan, Head of Manufacturing Supply Chain
• Dr. Mark Sumeray, Chief Medical Officer (Age 55)
• Mr. David Allmond, Chief Commercial Officer

Who are some of Amryt Pharma's key competitors?

Some companies that are related to Amryt Pharma include Corcept Therapeutics (CORT), Aurinia Pharmaceuticals (AUPH), Pacira BioSciences (PCRX), Emergent BioSolutions (EBS), TG Therapeutics (TGTX), Prothena (PRTA), Sage Therapeutics (SAGE), Harmony Biosciences (HRMY), Indivior (INVVY), Lyell Immunopharma (LYEL), Xencor (XNCR), Nektar Therapeutics (NKTR), Nuvation Bio (NUVB), Taro Pharmaceutical Industries (TARO) and Trillium Therapeutics (TRIL).
View all of AMYT's competitors.

What other stocks do shareholders of Amryt Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include Immunic (IMUX), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), Livongo Health (LVGO), Otonomy (OTIC), Akero Therapeutics (AKRO), Albireo Pharma (ALBO), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).

What is Amryt Pharma's stock symbol?

Amryt Pharma trades on the NASDAQ under the ticker symbol "AMYT."

Who are Amryt Pharma's major shareholders?

Amryt Pharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Stonepine Capital Management LLC (9.15%), Rubric Capital Management LP (5.14%), MPM Asset Management LLC (4.21%), Highbridge Capital Management LLC (2.58%), Rock Springs Capital Management LP (2.04%) and Man Group plc (1.47%).

Which institutional investors are selling Amryt Pharma stock?

AMYT stock was sold by a variety of institutional investors in the last quarter, including Context Advisory LLC.

Which institutional investors are buying Amryt Pharma stock?

AMYT stock was bought by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Stonepine Capital Management LLC, MPM Asset Management LLC, Rock Springs Capital Management LP, Highbridge Capital Management LLC, Man Group plc, Clearline Capital LP, and New Leaf Venture Partners L.L.C..

How do I buy shares of Amryt Pharma?

Shares of AMYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amryt Pharma's stock price today?

One share of AMYT stock can currently be purchased for approximately $9.62.

How much money does Amryt Pharma make?

Amryt Pharma has a market capitalization of $611.83 million and generates $182.61 million in revenue each year. The company earns $-104.53 million in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does Amryt Pharma have?

Amryt Pharma employs 2,020 workers across the globe.

What is Amryt Pharma's official website?

The official website for Amryt Pharma is www.amrytpharma.com.

Where are Amryt Pharma's headquarters?

Amryt Pharma is headquartered at DEPT 920A 196 HIGH ROAD WOOD GREEN, LONDON X0, D02 CR98.

How can I contact Amryt Pharma?

Amryt Pharma's mailing address is DEPT 920A 196 HIGH ROAD WOOD GREEN, LONDON X0, D02 CR98. The company can be reached via phone at 353-1518-0200 or via email at [email protected].